Luzitin Overview
- Year Founded
-
2005
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
Luzitin General Information
Description
Developer of innovative photosensitizing compounds intended for photodynamic therapy and photo diagnosis. The company's compounds can be used to treat cancer and other diseases that contribute to human wellness, enabling physicians to routinely practice the targeted therapy of solid tumors.
Contact Information
Website
www.luzitin.pt
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Edifício Bluepharma, Rua da Bayer
- S. Martinho do Bispo
- Coimbra, 3045-016
- Portugal
+351 239 000 000
Luzitin Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Secondary Transaction - Private | 01-Dec-2022 | 00.000 | Completed | Clinical Trials - Phase 2 | ||
| 1. Seed Round | 07-Dec-2010 | 00.000 | 00.000 | Completed | Clinical Trials - Phase 2 |
Luzitin Executive Team (5)
Luzitin Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Luís Arnaut Ph.D | Self | Co-Founder, President of the Advisory Board & Board Member | 000 0000 |
| Miguel Botto | Portugal Ventures | Board Member | 000 0000 |
| Paulo Barradas | Self | Board Member | 000 0000 |
| Sérgio Simões Ph.D | Luzitin | Chief Executive Officer & Executive Chairman | 000 0000 |